Drugs / Lipopolysaccharide
Lipopolysaccharide
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00949845 | Jan 2007 → ? | depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT05363527 | Mar 2023 → Dec 2025 | anxiety, atypical depressive disorder, depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT05751837 | Mar 2023 → May 2024 | digestive system cancer | Patrick Wagner, MD, FACS | Completed | No outcome recorded |
| Phase 1 | NCT03306589 | Aug 2017 → Jan 2018 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT04236986 | Mar 2017 → May 2023 | post-traumatic stress disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT04233593 | Mar 2014 → Aug 2021 | — | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01585350 | Oct 2012 → Jul 2014 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1 | NCT00246714 | Oct 2005 → Dec 2007 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00820989 | Feb 2000 → Feb 2011 | immune system disorder | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06620679 | May 2024 → Dec 2026 expected | — | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
| — | NCT02529592 | Feb → Apr 2015 | — | Karolinska Institutet | Completed | No outcome recorded |
| — | NCT01423968 | Jul 2011 → Dec 2012 | infectious disease with sepsis | University of Nottingham | Completed | No outcome recorded |
| — | NCT01452958 | Jun 2010 → Jan 2013 | glucose metabolism disease | Aarhus University Hospital | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT00753402 Comparator | Feb 2012 | immune system disorder | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 1/2 | NCT01978158 Background | Oct → Dec 2013 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00923910 Background | Feb 2008 → Oct 2013 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 4 | NCT01054989 Comparator | Mar 2009 → Sep 2011 | — | German Diabetes Center | Completed | No outcome recorded |
| — | NCT03551184 Comparator | Oct 2010 → Mar 2011 | — | Karolinska Institutet | Completed | No outcome recorded |
| — | NCT03551080 Comparator | Oct → Dec 2009 | — | Karolinska Institutet | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-03-06 | List Biological Laboratories, Inc | Endotoxins: Potency Testing and Low Endotoxin Recovery (LER/LLR) in Pharmaceutical Applications listlabs.com ↗ |
| 2014-06-17 | List Biological Laboratories, Inc | Lipopolysaccharide (LPS): Key Role in Immune Response and Research listlabs.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lipopolysaccharide | “pre-treatment with endotoxin (lipopolysaccharide or LPS) suppress the excessive immune response” NCT00246714 ↗12“Lipopolysaccharide (LPS; US Standard Reference endotoxin)” NCT01054989 ↗ “Endotoxin, Lipopolysaccharide, LPS” NCT00820989 ↗ “Endotoxin, Lipopolysaccharide, LPS” NCT00753402 ↗ |
| Known as | Endotoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00820989 ↗ |
| Known as | LPS | “lipopolysaccharide (LPS; endotoxin) will be administered to evoke a robust neuroimmune response” NCT04236986 ↗6“pre-treatment with endotoxin (lipopolysaccharide or LPS) suppress the excessive immune response” NCT00246714 ↗ “Lipopolysaccharide (LPS), single i.v. bolus, 0.4 ng/kg body weight” NCT06620679 ↗ “Lipopolysaccharide (LPS; US Standard Reference endotoxin)” NCT01054989 ↗ “Endotoxin, Lipopolysaccharide, LPS” NCT00753402 ↗ “Endotoxin, Lipopolysaccharide, LPS” NCT00820989 ↗ “lipopolysaccharide (LPS)” NCT01585350 ↗ |
| Known as | Purified LPS from Escherischa coli (O:113) | “Purified LPS from Escherischa coli (O:113)” NCT01978158 ↗ |
| Action | Activate | “TLR4 agonist lipopolysaccharide (LPS)” PMID 31248461 ↗ Jun 2019 |
| Modality | Other / unclassified | “Purified lipopolysaccharide prepared from E.Coli 0:113” NCT00923910 ↗ |
| Route | Intravenous | “bolus IV administration” NCT00753402 ↗ |